India Grants First Compulsory License To Natco For Bayer’s Nexavar; Disappointed, Bayer May Challenge Decision
This article was originally published in The Pink Sheet Daily
Executive Summary
India grants compulsory license to Natco for Bayer’s Nexavar; ruling could start run on more CLs.
You may also be interested in...
Biologics Data Protection In Trade Agreements Becoming Key Focus For PhRMA
At a House hearing PhRMA representative cites the need for 12 years test data exclusivity for biologics in the Trans-Pacific Partnership Agreement. Separately, USTR issues its 2012 Special 301 Report.
Bayer Says India's Natco Has No Ground For Compulsory License; Blames Lack of Drug Availability On Poor Health Infrastructure
MUMBAI - As Natco Pharma Ltd. is set to test the viability of India's highly debated compulsory licensing provisions by challenging Bayer AG's kidney and liver cancer treatment Nexavar (sorafenib), the German polymers-to-pharmaceuticals conglomerate has said that "extensive use of compulsory licenses will in the long-term undermine and threaten the patent system.
Cipla Targets Merck's Leading Anti-HIV Brand Isentress; Applies For Voluntary License In India
MUMBAI - Merck & Co.'s HIV integrase inhibitor Isentress (raltegravir) may have been a big success across many markets, but in India the anti-AIDS drug may be short of its mark. Leading home-grown company Cipla Ltd. has taken the route of applying for a "voluntary license" for the drug to New Jersey-headquartered Merck because Cipla says it is not reaching needy patients in India and it is priced exorbitantly